Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Income from Continuing Operations (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Income from Continuing Operations for 13 consecutive years, with 158325000.0 as the latest value for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 247.17% year-over-year to 158325000.0; the TTM value through Mar 2026 reached 472358000.0, down 268.29%, while the annual FY2025 figure was 359638000.0, 227.0% down from the prior year.
  • Income from Continuing Operations hit 158325000.0 in Q1 2026 for Viking Therapeutics, roughly flat from 157703000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15746000.0 in Q3 2022 and bottomed at 158325000.0 in Q1 2026.
  • Average Income from Continuing Operations over 5 years is 46030411.76, with a median of 24579000.0 recorded in 2023.
  • Year-over-year, Income from Continuing Operations fell 10.44% in 2023 and then tumbled 345.56% in 2025.
  • Viking Therapeutics' Income from Continuing Operations stood at 19551000.0 in 2022, then dropped by 25.72% to 24579000.0 in 2023, then tumbled by 44.0% to 35394000.0 in 2024, then plummeted by 345.56% to 157703000.0 in 2025, then fell by 0.39% to 158325000.0 in 2026.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 158325000.0, 157703000.0, and 90789000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.